Advertisement

Translational Stroke Research

, Volume 7, Issue 2, pp 111–119 | Cite as

Thrombolysis with Low-Dose Tissue Plasminogen Activator 3–4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan

  • Ryuta Morihara
  • Syoichiro Kono
  • Kota Sato
  • Nozomi Hishikawa
  • Yasuyuki Ohta
  • Toru Yamashita
  • Kentaro Deguchi
  • Yasuhiro Manabe
  • Yoshiki Takao
  • Kenichi Kashihara
  • Satoshi Inoue
  • Hideki Kiriyama
  • Koji Abe
Original Article

Abstract

Clinical data from Japan on the safety and real-world outcomes of alteplase (tPA) thrombolysis in the extended therapeutic window are lacking. The aim of this study was to assess the safety and real-world outcomes of tPA administered within 3–4.5 h of stroke onset. The study comprised consecutive acute ischemic stroke patients (n = 177) admitted across five hospitals between September 2012 and August 2014. Patients received intravenous tPA within <3 or 3–4.5 h of stroke onset. Endovascular therapy was used for tPA-refractory patients. In the 3–4.5 h subgroup (31.6 % of patients), tPA was started 85 min later than the <3 h group (220 vs. 135 min, respectively). However, outcome measures were not significantly different between the <3 and 3–4.5 h subgroups for recanalization rate (67.8 vs. 57.1 %), symptomatic intracerebral hemorrhage (2.5 vs. 3.6 %), modified Rankin Scale score of 0–1 at 3 months (36.0 vs. 23.4 %), and mortality (6.9 vs. 8.3 %). We present data from 2005 to 2012 using a therapeutic window <3 h showing comparable results. tPA following endovascular therapy with recanalization might be superior to tPA only with recanalization (81.0 vs. 59.1 %). Compared with administration within 3 h of ischemic stroke onset, tPA administration within 3–4.5 h of ischemic stroke onset in real-world stroke emergency settings at multiple sites in Japan is as safe and has the same outcomes.

Keywords

Acute stroke Edaravone Endovascular treatment Intracerebral hemorrhage Recanalization Tissue-type plasminogen activator 

Abbreviations

DWI

Diffusion-weighted imaging

DWI-ASPECTS

Diffusion-weighted imaging—Alberta Stroke Program Early Computed Tomography Score

ICH

Intracerebral hemorrhage

NIHSS

National Institutes of Health Stroke Scale

MRA

Magnetic resonance angiography

MRI

Magnetic resonance imaging

mRS

modified Rankin Scale

tPA

Tissue plasminogen activator

Notes

Compliance with Ethical Standards

The study was approved by the ethics committee of Okayama University (#1505-025).

Funding

This work was supported in part by Grants-in-Aid for Scientific Research (B) 2529320216 and (C) 24591263 and Grant-in-Aid for Challenging Research 24659651 from the Ministry of Education, Culture, Sports, Science and Technology, and by Grants-in-Aid from the Research Committees (H. Mizusawa, I. Nakano, M. Nishizawa, H. Sasaki, and M. Aoki) from the Ministry of Health, Labor and Welfare of Japan.

Conflict of Interest

Edaravone has been marketed in Japan since 2001 by Mitsubishi Tanabe Pharma (Osaka, Japan). K. Abe received honoraria from Mitsubishi Tanabe Pharma (Osaka, Japan) in 2012, 2013, and 2014. All remaining authors report no conflicts of interest.

References

  1. 1.
    Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303–9.CrossRefPubMedGoogle Scholar
  3. 3.
    The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40:2761–2768Google Scholar
  4. 4.
    Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–703.CrossRefPubMedGoogle Scholar
  5. 5.
    Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular diseases. 2008;25:457–507Google Scholar
  7. 7.
    Del Zoppo GJ, Saver JL, Jauch EC, Adams Jr HP. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945–8.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, et al. Canadian stroke best practice recommendations: secondary prevention of stroke guidelines, update 2014. Int J Stroke. 2015;10:282–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Clinical guidelines for stroke management 2010. Stroke Foundation web site. Available from http://www.strokefoundation.com.au/clinical-guidelines/. Accessed April 26, 2015.
  10. 10.
    Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, Mori E, et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cereb Dis Off J Natl Stroke Assoc. 2013;22:571–600.Google Scholar
  11. 11.
    Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke. 1988;19:480–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Otomo E, Tohgi H, Kogure K, Hirai S, Terashi A, Gotoh F, et al. Clinical efficacy of a free radical scavenger, MCI-186, on acute cerebral infarction: early phase II clinical trial. Ther Res. 1998;19:531–52.Google Scholar
  13. 13.
    Ohta Y, Takamatsu K, Fukushima T, Ikegami S, Takeda I, Ota T, et al. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med (Tokyo, Japan). 2009;48:593–6.CrossRefGoogle Scholar
  14. 14.
    The Edaravone Acute Brain Infarction Study Group. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457–507.CrossRefGoogle Scholar
  15. 15.
    Feng S, Yang Q, Liu M, Li W, Yuan W, Zhang S, et al. Edaravone for acute ischaemic stroke. The Cochrane database of systematic reviews. 2011:Cd007230.Google Scholar
  16. 16.
    Sharma P, Sinha M, Shukla R, Garg RK, Verma R, Singh MK. A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke. Ann Indian Acad Neurol. 2011;14:103–6.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, et al. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. J Stroke Cereb Dis Off J Natl Stroke Assoc. 2013;22:190–6.Google Scholar
  18. 18.
    Kono S, Deguchi K, Morimoto N, Kurata T, Yamashita T, Ikeda Y, et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. J Stroke Cereb Dis Off J Natl Stroke Assoc. 2013;22:1175–83.Google Scholar
  19. 19.
    Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9:866–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol. 2007;11:292–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry. 2005;76:1528–33.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Morita N, Harada M, Uno M, Matsubara S, Nagahiro S, Nishitani H. Evaluation of initial diffusion-weighted image findings in acute stroke patients using a semiquantitative score. Magn Reson Med Sci. 2009;8:47–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–82.CrossRefPubMedGoogle Scholar
  25. 25.
    Cronin CA, Sheth KN, Zhao X, Messe SR, Olson DM, Hernandez AF, et al. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. Stroke. 2014;45:2745–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39:1205–12.CrossRefPubMedGoogle Scholar
  27. 27.
    Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18.CrossRefPubMedGoogle Scholar
  29. 29.
    Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T, et al. Administration of edaravone, a free radical scavenger, during t-pa infusion can enhance early recanalization in acute stroke patients—a preliminary study. J Neurol Sci. 2012;313:132–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang W, Sato K, Hayashi T, Omori N, Nagano I, Kato S, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tpa in rat brain. Neurol Res. 2004;26:342–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb blood flow Metab Off J Int Soc Cereb Blood Flow Metab. 2009;29:715–25.CrossRefGoogle Scholar
  32. 32.
    Lukic-Panin V, Deguchi K, Yamashita T, Shang J, Zhang X, Tian F, et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res. 2010;7:319–29.CrossRefPubMedGoogle Scholar
  33. 33.
    Liu N, Shang J, Tian F, Nishi H, Abe K. In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice. Brain Res. 2011;1397:66–75.CrossRefPubMedGoogle Scholar
  34. 34.
    Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fat Acids. 1988;33:81–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ryuta Morihara
    • 1
  • Syoichiro Kono
    • 1
  • Kota Sato
    • 1
  • Nozomi Hishikawa
    • 1
  • Yasuyuki Ohta
    • 1
  • Toru Yamashita
    • 1
  • Kentaro Deguchi
    • 1
  • Yasuhiro Manabe
    • 2
  • Yoshiki Takao
    • 3
  • Kenichi Kashihara
    • 4
  • Satoshi Inoue
    • 5
  • Hideki Kiriyama
    • 5
  • Koji Abe
    • 1
  1. 1.Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityOkayamaJapan
  2. 2.Okayama National Hospital Medical CenterOkayamaJapan
  3. 3.Kurashiki Heisei HospitalKurashikiJapan
  4. 4.Okayama Kyokuto HospitalOkayamaJapan
  5. 5.Department of NeurosurgeryOkayama Citizens’ HospitalOkayamaJapan

Personalised recommendations